細胞名稱：人前列腺癌細胞；DU 145 [DU145；DU-145]培養(yǎng)
細胞形態(tài)： 細胞株
生長特性：貼壁 懸浮 半貼壁
傳代時間：2-3天 3-5天
傳代比例：1:2~1:3 1:1~1:2
儲存：液氮
保存與運輸： 干冰常溫運輸
細胞在培養(yǎng)瓶長成致密單層后，已基本上飽和，為使細胞能繼續(xù)生長，同時
也將細胞數(shù)量擴大，就必須進行傳代(再培養(yǎng))。 傳代培養(yǎng)也是一種將細胞種保存下去的方法。同時也是利用培養(yǎng)細胞進行各種實驗的必經(jīng)過程。懸浮型細胞直接分瓶就可以，而貼壁細胞需經(jīng)消化后才能分瓶。
人前列腺癌細胞；DU 145 [DU145；DU-145]培養(yǎng)細胞培養(yǎng)
1、冷凍管應(yīng)如何解凍？
取出冷凍管后， 須立即放入37 ℃水槽中快速解凍， 輕搖冷凍管使其在1 分鐘內(nèi)全部融化， 并注意水面不可超過冷凍管蓋沿， 否則易發(fā)生污染情形。另冷凍管由液氮桶中取出解凍時， 必須注意安全， 預(yù)防冷凍管之爆裂。
2、細胞冷凍管解凍培養(yǎng)時， 是否應(yīng)馬上去除DMSO？
除少數(shù)特別注明對DMSO 敏感之細胞外， 絕大部分細胞株（包括懸浮性細胞）， 在解凍之后， 應(yīng)直接放入含有10-15ml新鮮培養(yǎng)基之培養(yǎng)角瓶中， 待隔天再置換新鮮培養(yǎng)基以去除DMSO 即可， 如此可避免大部分解凍后細胞無法生長或貼附之問題。
3、可否使用與原先培養(yǎng)條件不同之培養(yǎng)基？
人前列腺癌細胞；DU 145 [DU145；DU-145]培養(yǎng)不能。每一細胞株均有其特定使用且已適應(yīng)之細胞培養(yǎng)基， 若驟然使用和原先提供之培養(yǎng)條件不同之培養(yǎng)基， 細胞大都無法立即適應(yīng)， 造成細胞無法存活。
4、可否使用與原先培養(yǎng)條件不同之血清種類？
不能。血清是細胞培養(yǎng)上一個極為重要的營養(yǎng)來源， 所以血清的種類和品質(zhì)對于細胞的生長會產(chǎn)生*的影響。來自不同物種的血清， 在一些物質(zhì)或分子的量或內(nèi)容物上都有所不同，血清使用錯誤常會造成細胞無法存活。
注意事項：
1. 收到細胞后首先觀察細胞瓶是否完好，培養(yǎng)液是否有漏液、渾濁等現(xiàn)象，若有上述現(xiàn)象發(fā)生請及時和我們。
2. 仔細閱讀細胞說明書，了解細胞相關(guān)信息，如細胞形態(tài)、所用培養(yǎng)基、血清比例、所需細胞因子等。
3. 用75%酒精擦拭細胞瓶表面，顯微鏡下觀察細胞狀態(tài)。因運輸問題貼壁細胞會有少量從瓶壁脫落，將細胞置于培養(yǎng)箱內(nèi)靜置培養(yǎng)，隔天再取出觀察。此時多數(shù)細胞均會貼壁，若細胞仍不能貼壁請用臺盼藍染色測定細胞活力，如果證實細胞活力正常，請將細胞離心后用新鮮培養(yǎng)基再次貼壁培養(yǎng)；如果染色結(jié)果顯示細胞無活力，請拍下照片及時和我們，信息確認后我們?yōu)槟倜赓M寄送一次。
4. 請客戶用相同條件的培養(yǎng)基用于細胞培養(yǎng)。培養(yǎng)瓶內(nèi)多余的培養(yǎng)基可收集備用，細胞傳代時可以一定比例和客戶自備的培養(yǎng)基混合，使細胞逐漸適應(yīng)培養(yǎng)條件。
5. 建議客戶收到細胞后前3天各拍幾張細胞照片，記錄細胞狀態(tài)，便于和公司技術(shù)部溝通交流。
6. 該細胞只能用于科研，不得用于臨床應(yīng)用。〖用途〗：生化研究。沉淀鉀、銣、銫、銨，以與鈉分離。

產(chǎn)品應(yīng)用   WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500
（石蠟切片需做抗原修復）
 not yet tested in other applications.
 optimal dilutions/concentrations should be determined by the end user. 
保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 This gene encodes two of three subunit types of the membrane-bound enzyme N-acetylglucosamine-1-phosphotransferase, a heterohexameric complex composed of two alpha, two beta, and two gamma subunits. The encoded protein is proteolytically cleaved at the Lys928-Asp929 bond to yield mature alpha and beta polypeptides while the gamma subunits are the product of a distinct gene (GeneID 84572). In the Golgi apparatus, the heterohexameric complex catalyzes the first step in the synthesis of mannose 6-phosphate recognition markers on certain oligosaccharides of newly synthesized lysosomal enzymes. These recognition markers are essential for appropriate trafficking of lysosomal enzymes. Mutations in this gene have been associated with both mucolipidosis II and mucolipidosis IIIA.[provided by RefSeq, May 2010].
Function : Catalyzes the formation of mannose 6-phosphate (M6P) markers on high mannose type oligosaccharides in the Golgi apparatus. M6P residues are required to bind to the M6P receptors (MPR), which mediate the vesicular transport of lysosomal enzymes to the endosomal/prelysosomal compartment.
Subunit : Hexamer of two alpha, two beta and two gamma subunits; disulfide-linked. It is believed that the alpha and/or the beta subunit of the enzyme contain the catalytic portion and that the gamma subunit functions in recognition of the lysosomal enzymes.
Subcellular Location : N-acetylglucosamine-1-phosphotransferase subunit alpha: Golgi apparatus membrane; Single-pass type I membrane protein.
N-acetylglucosamine-1-phosphotransferase subunit beta: Golgi apparatus membrane; Single-pass type II membrane protein.
Tissue Specificity : Expressed in the heart, whole brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
Post-translational modifications : The alpha- and beta-subunits appear to be generated by a proteolytic cleavage at the Lys-928-Asp-929 bond.
DISEASE : Defects in GNPTAB are the cause of mucolipidosis type II (MLII) [MIM:252500]; also known as inclusion cell disease or I-cell disease (ICD). MLII is a fatal, autosomal recessive, lysosomal storage disorder characterized by severe clinical and radiologic features, peculiar fibroblast inclusions, and no excessive mucopolysacchariduria. Congenital dislocation of the hip, thoracic deformities, hernia, and hyperplastic gums are evident soon after birth.
Defects in GNPTAB are the cause of mucolipidosis type III complementation group A (MLIIIA) [MIM:252600]; also known as variant pseudo-Hurler polydystrophy. MLIIIA is an autosomal recessive disease of lysosomal enzyme targeting. Clinically MLIII is characterized by restricted joint mobility, skeletal dysplasia, and short stature. Mildly coarsened facial features and thickening of the skin have been described. Cardiac valvular disease and corneal clouding may also occur. Half of the reported patients show learning disabilities or mental retardation.
Similarity : Belongs to the stealth family.
Contains 1 EF-hand domain.
Contains 2 LNR (Lin/Notch) repeats.
Database links : UniProtKB/Swiss-Prot: Q3T906.1

 
英文名稱  Anti-GNPTG
中文名稱  溶酶體累積病相關(guān)蛋白/口吃相關(guān)蛋白抗體
別    名  GlcNAc phosphotransferase gamma subunit; GlcNAc-1-phosphotransferase subunit gamma; GNPTAG; LP2537; N-acetylglucosamine-1-phosphate transferase gamma subunit; RJD9; UDP-N-acetylglucosamine-1-phosphotransferase subunit gamma; GNPTG_HUMAN.
濃    度  1mg/1ml
規(guī) 格  0.2ml/200μg    
抗體來源  Rabbit 
克隆類型  polyclonal
交叉反應(yīng)  Human, Mouse, Rat, Dog
產(chǎn)品類型  一抗   
研究領(lǐng)域  腫瘤 細胞生物 信號轉(zhuǎn)導 細胞類型標志物 新陳代謝 
蛋白分子量  predicted molecular weight: 32kDa
性    狀  Lyophilized or Liquid
免 疫 原  KLH conjugated synthetic peptide derived from human GNPTG
亞    型  IgG
純化方法  affinity purified by Protein A
儲 存 液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產(chǎn)品應(yīng)用   WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500
（石蠟切片需做抗原修復）
 not yet tested in other applications.
 optimal dilutions/concentrations should be determined by the end user. 
保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 This gene encodes the gamma sunbunit of the N-acetylglucosamine-1-phosphotransferase complex. This hexameric complex, composed of alpha, beta and gamma subunits, catalyzes the first step in synthesis of a mannose 6-phosphate lysosomal recognition marker. This enzyme complex is necessary for targeting of lysosomal hydrolases to the lysosome. Mutations in the gene encoding the gamma subunit have been associated with mucolipidosis IIIC, also known as mucolipidosis III gamma.[provided by RefSeq, Feb 2010].
Function : May recognize the substrate of GlcNAc-1-phosphotransferase but also the lysosomal proteins with mannose-6-phosphate residues.
Subunit : Hexamer of two alpha, two beta and two gamma subunit; disulfide-linked. It is believed that the alpha and/or the beta subunit of the enzyme contain the catalytic portion and that the gamma subunit functions in recognition of the lysosomal enzymes.
Subcellular Location : Golgi Apparatus and Secreted.
Tissue Specificity : Widely expressed.
DISEASE : Defects in GNPTG are the cause of mucolipidosis type III complementation group C (MLIIIC) [MIM:252605]; also known as variant pseudo-Hurler polydystrophy. MLIIIC is an autosomal recessive disease of lysosomal hydrolase trafficking. Unlike the related diseases, mucolipidosis II and IIIA, the enzyme affected in mucolipidosis IIIC (GlcNAc-phosphotransferase) retains full transferase activity on synthetic substrates but lacks activity on lysosomal hydrolases. Typical clinical findings include stiffness of the hands and shoulders, claw-hand deformity, scoliosis, short stature, coarse facies, and mild mental retardation. Radiographically, severe dysostosis multiplex of the hip is characteristic and frequently disabling. The clinical diagnosis can be confirmed by finding elevated serum lysosomal enzyme levels and/or decreased lysosomal enzyme levels in cultured fibroblasts.
Similarity : Contains 1 PRKCSH domain.
Database links : UniProtKB/Swiss-Prot: Q9UJJ9.1

英文名稱  Anti-GNRH2/GnRH II
中文名稱  *釋放激素2抗體
別    名  GnRH II; GnRH-associated peptide 2; GnRH-associated peptide II; gnrh2; GON2_HUMAN; Gonadoliberin II; Gonadotropin-releasing hormone 2; Gonadotropin-releasing hormone II; LH-RH II; Luliberin II; Luteinizing hormone-releasing hormone II; Progonadoliberin 2; Progonadoliberin II.
濃    度  1mg/1ml
規(guī) 格  0.2ml/200μg    
抗體來源  Rabbit 
克隆類型  polyclonal
交叉反應(yīng)  Human
產(chǎn)品類型  一抗   
研究領(lǐng)域  細胞生物 發(fā)育生物學 信號轉(zhuǎn)導 生長因子和激素 G蛋白信號 
蛋白分子量  predicted molecular weight: 11kDa
性    狀  Lyophilized or Liquid
免 疫 原  KLH conjugated synthetic peptide derived from human GNRH2/GnRH II
亞    型  IgG
純化方法  affinity purified by Protein A
儲 存 液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
產(chǎn)品應(yīng)用   WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500